AIDS researchers have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases. The study, published today in PLoS ONE, demonstrates that human stem cells can be engineered into the equivalent of a genetic vaccine.
By Taking CD8 cytotoxic T lymphocytes — the "killer" T cells that help fight infection — from an HIV-infected individual, the researchers identified the molecule known as the T-cell receptor, which guides the T cell in recognizing and killing HIV-infected cells.
These cells, while able to destroy HIV-infected cells, do not exist in enough quantities to clear the virus from the body. So the researchers cloned the receptor and genetically engineered human blood stem cells, then placed the stem cells into human thymus tissue that had been implanted in mice, allowing them to study the reaction in a living organism.
The engineered stem cells developed into a large population of mature, multifunctional HIV-specific CD8 cells that could specifically target cells containing HIV proteins. The researchers also found that HIV-specific T-cell receptors have to be matched to an individual in much the same way that an organ is matched to a transplant patient.
"We have demonstrated in this proof-of-principle study that this type of approach can be used to engineer the human immune system, particularly the T-cell response, to specifically target HIV-infected cells," said lead investigator Scott G. Kitchen, assistant professor of medicine in the division of hematology and oncology at UCLA.
"These studies lay the foundation for further therapeutic development that involves restoring damaged or defective immune responses toward a variety of viruses that cause chronic disease, or even different types of tumors."
The next step is to test this strategy in a more advanced model to determine if it would work in the human body, said co-author Jerome A. Zack, UCLA professor of medicine in the division of hematology and oncology and associate director of the UCLA AIDS Institute. The researchers also hope to expand the range of viruses against which this approach could be used.
Citation: Kitchen SG, Bennett M, Galić Z, Kim J, Xu Q, et al., 'Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice', PLoS ONE 2009, 4(12): e8208. doi:10.1371/journal.pone.0008208
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- How A Former Naturopath Can Help Unravel The Trickery of Alternative Medicine
- Can A New Rule Trigger A Second EU Referendum? Petition Signatures Over 10% Of Total Votes Cast
- Better Brains With Beer
- What Did Earth's Ancient Magnetic Field Look Like?
- Some Celiac Disease May Be Due To Viruses
- Beneficial Bacteria May Protect Breasts From Cancer
- Finding All-Hadronic Top - Again
- "It sounds somewhat familiar. Just has here in the states we elect people to A..."
- "Of life on the island VS life on the mainland. Yeah. I've heard the same from people..."
- "Some observations for you First of all it seems that you like the other 3.5 million plus people..."
- "It's not evidence. It's just people who don't know the difference between a lens flare, an offset..."
- "I will lean more to the ethics of 23 and Me in that there is no state coercive force of State involved..."
- Chemistry Can Help Roast the Perfect Coffee Bean
- What Happens To A Soccer Player’s Brain After Missing A Penalty Kick
- It’s Back to Shots for Flu Prevention
- ACSH Applauds Media Awareness of the Fentanyl Crisis
- Counting Bites Examined, to Help Decrease Food Intake
- The Safe And Unsafe Nutty Treats For Your Pup
- How to stop the United Nations from abusing its immunity
- Study examines quality of end life care for patients with different illnesses
- Improvements needed in end-of-life care for patients with organ failure
- Georgetown Institute launches real-time study of smartphone fertility app use
- After Brexit, Italy May Be Next